UBS Group
AYTU icon

UBS Group’s AYTU BioPharma AYTU Stock Holding History

UBS Group’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.54K Sell
1,663
-1,386
-45% -$3.54K ﹤0.01% 8925
2025
Q4 		$7.93K Sell
3,049
-86
-3% -$193 ﹤0.01% 8413
2025
Q3 		$5.89K Buy
3,135
+88
+3% +$203 ﹤0.01% 8820
2025
Q2 		$6.64K Buy
3,047
+2,785
+1,063% +$4.33K ﹤0.01% 9074
2025
Q1 		$314 Sell
262
-1,234
-82% -$1.8K ﹤0.01% 9830
2024
Q4 		$2.54K Buy
1,496
+1,236
+475% +$2.26K ﹤0.01% 9032
2024
Q3 		$611 Sell
260
-48
-16% -$124 ﹤0.01% 8868
2024
Q2 		$899 Sell
308
-718
-70% -$2.17K ﹤0.01% 8742
2024
Q1 		$3.12K Buy
1,026
+766
+295% +$2.19K ﹤0.01% 7771
2023
Q4 		$738 Sell
260
-3,904
-94% -$10.8K ﹤0.01% 8529
2023
Q3 		$11.2K Buy
4,164
+3,904
+1,502% +$6.83K ﹤0.01% 7066
2023
Q2 		$416 Sell
260
-5,013
-95% -$9.84K ﹤0.01% 8248
2023
Q1 		$11.8K Buy
5,273
+5,012
+1,920% +$14.7K ﹤0.01% 7476
2022
Q4 		$991 Sell
261
-2,600
-91% -$9.79K ﹤0.01% 10002
2022
Q3 		$11K Buy
2,861
+2,554
+832% +$19.4K ﹤0.01% 8273
2022
Q2 		$4K Buy
+307
New +$3.93K ﹤0.01% 9037
2022
Q1 		– Sell
-732
Closed -$18.2K – 10235
2021
Q4 		$20K Buy
732
+653
+827% +$28.2K ﹤0.01% 7828
2021
Q3 		$5K Buy
79
+33
+72% +$2.48K ﹤0.01% 8515
2021
Q2 		$5K Sell
46
-87
-65% -$10.2K ﹤0.01% 8529
2021
Q1 		$20K Sell
133
-220
-62% -$34.9K ﹤0.01% 7372
2020
Q4 		$42K Buy
+353
New +$64.3K ﹤0.01% 6332
2020
Q3 		– Sell
-130
Closed -$33.4K – 7970
2020
Q2 		$36K Buy
130
+106
+442% +$32.1K ﹤0.01% 6133
2020
Q1 		$8K Buy
24
+8
+50% +$1.54K ﹤0.01% 7063
2019
Q4 		$3K Buy
+16
New +$3.07K ﹤0.01% 7731
2019
Q3 		– Sell
-22
Closed -$6.62K – 7985
2019
Q2 		$8K Sell
22
-23
-51% -$8.77K ﹤0.01% 7175
2019
Q1 		$15K Buy
+45
New +$11.2K ﹤0.01% 6530
2018
Q4 		– Sell
-42
Closed -$23K – 8013
2018
Q3 		$23K Buy
42
+29
+223% +$26.8K ﹤0.01% 6718
2018
Q2 		$13K Buy
13
+12
+1,200% +$20K ﹤0.01% 6973
2018
Q1 		$2K Buy
+1
New +$6.88K ﹤0.01% 7518
2017
Q4 		– Hold
0
– – – 7521

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's AYTU Position: Q1 2026 in Review

UBS Group reduced its AYTU BioPharma (AYTU) stake by 45% in Q1 2026, selling an estimated $3.54K and leaving 1,663 shares worth $4.54K. The position accounts for ﹤0.01% of the portfolio, ranked #8925.

UBS Group first reported a position in AYTU in Q1 2018 and has held it in 29 quarters since. The position peaked at $42K in Q4 2020. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • UBS Group held 1,663 shares of AYTU BioPharma worth $4.54K as of Q1 2026.
  • UBS Group sold 1,386 AYTU BioPharma shares in Q1 2026, an estimated $3.54K.
  • AYTU BioPharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8925 holding.
  • UBS Group first reported a position in AYTU BioPharma in Q1 2018 and has held it in 29 quarters since.
  • UBS Group's AYTU BioPharma position peaked at $42K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.